NewsAvi Kapoor
Sensus Healthcare
SRTS · NASDAQ
$2.75−$0.01 (−0.36%)TodayMarket closed ·
Prev close $2.76
Latest news
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Full Transcript: Sensus Healthcare Q2 2026 Earnings Call
- Press releaseBusiness Wire
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
- Press releaseBusiness Wire
Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
- Press releaseBusiness Wire
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
- Press releaseBusiness Wire
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseBusiness Wire
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
- Press releaseBusiness Wire
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer
- Press releaseBusiness Wire
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
- Press releaseBusiness Wire
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
- Press releaseBusiness Wire
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
- Press releaseBusiness Wire
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer
- Press releaseBusiness Wire
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors
- Press releaseBusiness Wire
Sensus Healthcare Reports Third Quarter 2025 Financial Results
- Press releaseBusiness Wire
Sensus Healthcare Named to TIME's America's Growth Leaders of 2026
- News
Earnings Scheduled For November 6, 2025
- Press releaseBusiness Wire
CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
- Press releaseBusiness Wire
Sensus Healthcare Announces the Passing of Director Bill McCall
- Press releaseBusiness Wire
Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6
- Press releaseGlobe Newswire
SENSUS INVESTIGATION REMINDER: Bragar Eagel & Squire, Reminds Sensus Healthcare Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Sensus Stockholders
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
- Press releaseBusiness Wire
Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare's SRT Combined with Punch Excision to Treat Keloids
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.